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Rituximab is a chimeric human/mouse monoclonal antibody that is approved for the treatment of relapsed and refractory non-
Hodgkin’s lymphoma (NHL) and in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
chemotherapy as first-line therapy for diffuse large B-cell NHL, where it has shown the first survival advantage over CHOP alone
in more than 20 years. Strategies to help define the optimal therapeutic usage of rituximab are being assessed, including first-line and
maintenance or extended therapy, and the combination of rituximab with chemotherapy in indolent NHL. Emerging data suggest that
earlier use may yield higher response rates, extended therapy can prolong remission, and the addition of rituximab to chemotherapy
can increase clinical and molecular remission rates when compared with those achieved using chemotherapy alone. Studies in the
peritransplant setting suggest a role for rituximab in vivo purging prior to transplant and/or maintenance rituximab as a means of
clearing minimal residual disease. Rituximab has also shown activity in other B-cell disorders such as chronic lymphocytic leukaemia.
The full potential of this immunotherapeutic agent remains to be defined in ongoing and future clinical trials.
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Combination chemotherapy has markedly improved outcome in
aggressive non-Hodgkin’s lymphoma (NHL) since its introduction
in the 1970s, but is curative in less than half of the patients. In
indolent NHL, the impact of chemotherapy has been much lower;
while response rates and progression-free survival (PFS) may be
improved, overall survival (OS) has not increased and advanced
indolent NHL remains essentially incurable without allogeneic
bone marrow transplant.
A number of newer approaches to improve outcome are under
investigation, including the use of monoclonal antibodies targeted
against specific antigens expressed by lymphoma cells. The cell
surface antigen CD20 is in many ways an ideal target: it is
expressed by 95% of B-cell NHL cases but not on haematopoietic
stem cells; it has a functional role in B-cell growth and also does
not normally circulate as a free antigen in the plasma, so free
antigen does not compete for antibody binding.
Rituximab is an anti-CD20 chimeric monoclonal antibody and
was the first antibody approved for treatment of NHL. Multiple
mechanisms of action for rituximab have been identified by in vitro
studies. These include complement-dependent cytotoxicity (CDC),
antibody-dependent cellular cytotoxicity (ADCC) and induction of
apoptosis (reviewed by Maloney et al, 2002). Rituximab is also able
to sensitise lymphoma cells to the cytotoxic activity of chemother-
apy. There is now a substantial body of data describing the clinical
use of rituximab in NHL, which we review here.
PREVIOUSLY UNTREATED INDOLENT NHL
Several studies have examined rituximab as a first-line therapy in
patients with indolent NHL (Colombat et al, 2001; Witzig et al,
2002; Hainsworth, 2003). This treatment approach has yielded
consistently high response rates (overall response rate (ORR) 61–
73%, with 20–37% complete responses (CR)) (Colombat et al,
2001; Witzig et al, 2002; Hainsworth, 2003) (Table 1). It appears
that extended therapy (induction followed by maintenance) may
be better than rituximab induction only: recent 2-year follow-up
data from a phase II trial of first-line and maintenance rituximab
(Hainsworth, 2003) showed high ORRs and CRs (73 and 37%,
respectively), and a median PFS of 34 months at a median 30-
month follow-up. A phase III trial has compared maintenance
therapy vs observation only following rituximab induction
(Ghielmini et al, 2002). Of 202 patients enrolled, 151 responded
or had stable disease following a 4-week course of rituximab, and
were randomised to either rituximab maintenance (four once-
weekly doses, every 2 months 4) or to observation. At a median
follow-up of 35 months, the rituximab maintenance group was
found to have a 43% reduced risk of progression (median event-
free survival (EFS) 23 vs 12 months; P¼0.02), with no increase in
treatment-related adverse events. In the previously untreated
patients, the difference in EFS was even greater (36 vs 19 months;
P¼0.009).
The efficacy and tolerability of rituximab suggest that it may be
particularly useful as a first-line single-agent therapy in elderly
patients, and also in young women who want to preserve their
fertility. It may also have a role as a first-line therapy in
asymptomatic patients with advanced disease (stages 3 or 4),
aiming to prolong the asymptomatic period. This will need to be
assessed in clinical trials, however.
Rituximab plus chemotherapy in previously untreated
indolent NHL
The single-agent activity of rituximab, coupled with its distinct
mechanisms of action, nonoverlapping toxicity and ability to
sensitise lymphoma cells to cytotoxic activity, has encouraged
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(CHOP or CVP) has demonstrated high activity, achieving a
response rate of around 97% (57% CR) in 82 patients with
previously untreated follicular lymphoma (Hainsworth et al, 2002).
In all, 85% of patients with follicular lymphoma carry a
characteristic chromosomal translocation, t(14;18), leading to
overexpression of bcl-2, an antiapoptotic gene that may serve as
a survival factor for lymphoma cells and can be detected by
polymerase chain reaction (PCR). Achievement of molecular
remission post-therapy (clearance of bcl-2 positive cells) appears
to be associated with prolonged PFS and may even predict longer
OS (Freedman et al, 1999).
Another study with rituximab plus FND (fludarabine, novan-
trone, dexamethasone) chemotherapy has shown high rates of
molecular remission in the peripheral blood (90%) and bone
marrow (76%) of patients with previously untreated follicular
lymphoma at a 6-month follow-up (Cabanillas et al, 2000). The
most extensively evaluated regimen, rituximab plus CHOP, has
produced response rates of up to 100% (including 58% CRs) in
both treatment-naı ¨ve and pretreated follicular lymphoma patients,
with an impressive median PFS in excess of 65 months (Czuczman
et al, 2001b). Similar results have been obtained using rituximab
plus fludarabine (Czuczman et al, 2001a). Rituximab-containing
chemotherapy regimens appear to increase both clinical and
molecular remission rates when compared with those usually
achieved with chemotherapy only, giving grounds for optimism
that they may also result in improved PFS.
Rituximab has also been assessed as consolidation treatment in
patients with minimal residual disease (MRD) (bcl-2 positivity in
the presence of complete clinical remission) after CHOP or
fludarabine/mitoxantrone (FM) chemotherapy (Zinzani, 2002).
The aim of the consolidation treatment was to obtain molecular
remission and prolong PFS. An increase in molecular remission
was observed after rituximab consolidation in both chemotherapy
groups, from 20 to 40% in the CHOP group and from 34 to 59% in
the FM group. Sequential therapy with short-course chemotherapy
followed by rituximab has also been investigated in previously
untreated patients (Rambaldi et al, 2002), and the results are
similar to those for concurrent therapy. The combination of
rituximab plus CVP (chlorambucil, vincristine, prednisone) vs
CVP alone as first-line therapy for indolent NHL is currently being
studied in a phase III randomised trial (M39021 Trial).
RELAPSED INDOLENT NHL
Rituximab is established in the treatment of relapsed indolent
NHL, being both effective and well tolerated. The pivotal trial in
this setting included 166 patients with relapsed low-grade or
follicular lymphoma who were assigned to receive four once-
weekly doses of rituximab 375mgm
 2 (McLaughlin et al, 1998).
The ORR was 48%, with a median time to progression (TTP) of 13
months in responders.
Prolonged single-agent rituximab (Piro et al, 1999) and/or
retreatment (Davis et al, 2000) in patients with relapsed disease are
both feasible and may have a beneficial effect on response rate and
PFS. Extended rituximab therapy has been shown to achieve a
response rate of 60% and a median disease-free survival in excess
of 19 months (Piro et al, 1999), providing a rationale for
maintenance rituximab in the first-line setting. These strategies
may be particularly useful for patient groups such as the elderly,
who may not be able to tolerate conventional chemotherapy or
immunochemotherapy.
Rituximab plus chemotherapy for relapsed indolent NHL
Single-agent rituximab is active in patients with relapsed indolent
lymphoma, but the remissions are no more durable than with
conventional chemotherapy, and patients eventually relapse.
Attempts to improve PFS by combining rituximab with che-
motherapy are currently being undertaken. A study by the German
Low-Grade Lymphoma Study Group is comparing the combina-
tion of fludarabine, cyclophosphamide and mitoxantrone (FCM)
with rituximab plus FCM in patients with relapsed follicular and
mantle cell lymphoma (MCL), and interim analyses have reported
a response rate of 83% for the immunochemotherapy arm
compared with 53% for FCM alone (Hiddemann et al, 2001),
indicating that combined modality treatment may be superior to
chemotherapy alone.
Many studies now suggest that combination immunochem-
otherapy may be more effective than single-agent rituximab or
chemotherapy alone, and thus this treatment may be offered to
patients with relapsed disease who can tolerate a combined
regimen. However, the results of prospective comparative trials are
still needed to confirm the superiority of immunochemotherapy in
this setting.
MANTLE CELL LYMPHOMA
Patients with MCL have poor prognosis and curative treatment
options are limited. As the majority of MCL express CD20, there is
a clear rationale for the use of rituximab in this setting. A large,
phase II study, assessing the efficacy of single-agent rituximab in
74 patients with newly diagnosed or relapsed MCL (34 and 40
patients, respectively), demonstrated a response rate of 34% with a
median PFS of 14 months (Foran et al, 2000), confirming the
activity of rituximab in MCL.
Given the poor prognosis of MCL, high-dose therapy (HDT)
with autologous stem cell transplantation (ASCT) is being
increasingly considered for patients achieving their first complete
remission. Addition of rituximab to HDT/ASCT has been evaluated
by Mangel et al (2002), who, in a matched pair analysis, showed
that patients who received rituximab purging during intensive
conditioning for ASCT achieved significantly better PFS, with a
trend towards longer OS, than historical controls who received
Table 1 Rituximab in NHL
Disease setting Therapy n ORR (%) CR (%) Reference
Untreated indolent Single-agent rituximab 50 73 27 Colombat et al (2001)
Untreated indolent Single-agent rituximab 60 47 7 Hainsworth (2003)
Untreated indolent Single-agent rituximab 37 62 44 Witzig et al (2002)
Relapsed aggressive Rituximab+EPOCH 50 64 26 Jost et al (2001)
Relapsed aggressive Rituximab+ICE 31 81 55 Kewalramani et al (2001)
Relapsed aggressive Rituximab+paclitaxel/ topotecan 45 69 44 Younes et al (2001)
Untreated CLL Rituximab+fludarabine 104 90 47 Byrd et al (2003)
Untreated/relapsed CLL Rituximab+fludarabine 30 90 33 Schulz et al (2002)
Untreated CLL Rituximab+fludarabine/ cyclophosphamide 135 95 67 Wierda et al (2002)
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fludarabine). Another study in this setting found that all 20
assessable patients achieved lymphoma-free stem cell harvests (by
PCR analysis) following intensified induction with rituximab in
vivo purging, while 26 of the 28 patients were alive and disease-free
at a median follow-up of 22 months (Gianni et al, 2002).
Romaguera et al (2001) treated 77 patients with previously
untreated MCL with a combination of rituximab plus HyperCVAD.
A response rate of 89% was obtained and, interestingly, failure-free
survival and OS in younger patients were similar to that previously
achieved using the HyperCVAD regimen in combination with
HDT/ASCT. The addition of rituximab to the HyperCVAD regimen
may, therefore, result in durable remissions without the need for
ASCT.
RITUXIMAB IN AGGRESSIVE NHL
The activity of single-agent rituximab in relapsed aggressive NHL
has been demonstrated, but the strongest data in aggressive NHL
have come from studies of combination immunochemotherapy,
particularly rituximab plus CHOP (R-CHOP). Vose et al (2001)
reported a response rate of 94%, with 61% CR, for R-CHOP in 33
patients with previously untreated aggressive NHL. Long-term
(median 62-month) follow-up of these 33 patients has recently
reported an OS and PFS of 87 and 80%, respectively (Vose et al,
2002).
A prospective randomised trial in 399 elderly patients (aged 60–
80 years) with previously untreated diffuse large B-cell lymphoma
(DLCL) demonstrated a significant advantage for R-CHOP over
CHOP alone (Coiffier et al, 2002). Patients in the R-CHOP group
had a higher CR rate (75 vs 63%, P¼0.005), improved PFS (2-year
disease progression 9 vs 22%, P¼0.007; 2-year relapse rate 14 vs
25%, P¼0.002) and increased EFS and OS (2-year EFS 57 vs 38%,
Po0.001; 2-year OS 70 vs 57%, P¼0.007). No significant
difference in treatment-related toxicity was seen between the
groups. In an interim subset analysis of 328 patients, it was shown
that R-CHOP was superior to CHOP alone in both low-risk and
high-risk patients, and also in patients aged 60–70 or 70–80 years
(Coiffier et al, 2001). This study has identified R-CHOP as the gold
standard therapy in elderly patients with DLCL and the results of a
similar ongoing study in younger patients are awaited (MInT).
Rituximab for relapsed aggressive NHL
HDT followed by ASCT is the preferred treatment for younger
patients with relapsed aggressive lymphoma that is responsive to
conventional salvage regimens. Several studies have shown good
ORRs and CRs (ORR 60–80% with CR 25–60%) in patients treated
with a rituximab-containing salvage regimen which appear super-
ior to those achieved with chemotherapy alone (Table 1).
RITUXIMAB IN STEM CELL TRANSPLANTATION
While HDT/ASCT may be considered a potentially curative
therapy for aggressive NHL, approximately 40–60% of patients
with aggressive NHL, and most patients with indolent NHL, will
eventually relapse following transplant. Relapse post-transplant is
due either to contamination of the stem cell harvest or persistence
of MRD post-HDT. A number of strategies have therefore been
employed in attempts to prevent/reduce stem cell contamination
(stem cell purging) and/or eradicate lymphoma cells that survived
HDT (post-transplant ‘mopping up’).
Patients with follicular lymphoma whose bone marrow harvests
are cleared of bcl-2-positive cells have increased relapse-free
survival compared with patients whose bone marrow harvests
remain positive (Freedman et al, 1999). Whereas the efficacy of
immunological ex vivo purging (using monoclonal antibodies) is
limited (up to 58% of harvests remain bcl-2 positive), in vivo
purging with rituximab has produced bcl-2-negative harvests in
69–90% of stem cell harvests without compromising stem cell
yield or function (reviewed by Gisselbrecht and Mounier, 2003).
Rituximab in vivo purging pretransplant results in a high rate of
molecular remissions post-transplant, and favourable PFS (re-
viewed by Gisselbrecht and Mounier, 2003). A number of studies
have demonstrated an increase in molecular remission using
rituximab post-transplant (Horwitz et al, 2001; Brugger et al,
2002), but it remains to be seen whether these translate into
durable clinical remissions. Whether there is, in fact, a significant
survival advantage using rituximab peritransplant, however,
remains to be determined in prospective randomised studies.
The ongoing EBMT Lym-1 trial randomises patients with follicular
lymphoma to receive ASCT with or without in vivo purging with
rituximab, as well as to post-transplant rituximab vs observation.
This and other ongoing studies in both indolent and aggressive
NHL will help to define the role of rituximab in the peritransplant
setting.
RITUXIMAB IN CHRONIC LYMPHOCYTIC
LEUKAEMIA
The efficacy and tolerability of rituximab have been evaluated in
other haematological disorders, most notably chronic lymphocytic
leukaemia (CLL) and small lymphocytic lymphoma (SLL), the
lymphomatous equivalent of CLL. However, single-agent ritux-
imab has yielded low response rates (approximately 15%) in
patients with relapsed CLL/SLL (McLaughlin et al, 1998; Piro et al,
1999). In contrast, the response rate in patients with previously
untreated CLL/SLL was much higher (56%, with 8% CR) (Hains-
worth, 2003). Given the low responses seen in relapsed disease,
increased dosing and dose escalation have been evaluated as
strategies to increase response to rituximab (Byrd et al, 2001;
O’Brien et al, 2001). Both were shown to increase response rates to
between 45 and 75%, but these strategies are not feasible in routine
medical practice. The combination of chemotherapy with ritux-
imab appears to be well tolerated and effective in CLL. Studies of
rituximab with fludarabine-containing regimens, based on pre-
vious data showing an in vitro synergy between fludarabine and
rituximab (Alas et al, 2000), reported high response rates of 90–
95% (CR of 33–67%) (Schulz et al, 2002; Wierda et al, 2002; Byrd
et al, 2003) (Table 1). The impact of these clinical responses on PFS
and OS remains to be determined.
RITUXIMAB IN OTHER HAEMATOLOGICAL
DISORDERS
Rituximab has been evaluated in a range of other B-cell
malignancies, including post-transplant lymphoproliferative dis-
order (PTLD), Waldenstro ¨m’s disease and HIV-associated lym-
phoma. Data from two studies indicate that approximately 50% of
the patients with PTLD may respond to rituximab monotherapy,
and CRs of 33 and 52% have been reported (Choquet et al, 2002;
Oertel et al, 2002). Rituximab has produced response rates of 40–
86% in Waldenstro ¨m’s macroglobulinaemia with some evidence
for CRs, especially when used in combination with fludarabine
(Byrd et al, 1999; Treon et al, 2002). Patients with HIV-related
NHL have shown very encouraging responses to rituximab with
ORRs and CR rates of approximately 80% (Boue et al, 2002).
Although patient numbers are low, the data for rituximab in
lymphocyte predominant Hodgkin’s disease are also encouraging.
Rituximab has also been evaluated in nonmalignant B-cell
disorders. In immune thrombocytopenic purpura (ITP), single-
agent rituximab has demonstrated responses in up to 72% of
patients, with CR in 32% and a response duration of 12þ months
for patients in CR (Cooper et al, 2002). The highest response rates
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suggesting that rituximab may be a valuable agent for patients with
few other treatment options. Promising results have also been
demonstrated in autoimmune haemolytic anaemia, where all
patients have responded to both treatment and retreatment with
rituximab (Gupta et al, 2001). Taken together, the studies indicate
the potential of rituximab in B-cell disorders, and the need for
further assessment of its efficacy and tolerability in these settings.
TOLERABILITY OF RITUXIMAB
Single-agent studies have reported the good tolerability of
rituximab. The most common adverse events are infusion-related
reactions, comprising mainly fever and chills, in more than 50% of
patients. These occur usually within hours of the first infusion and
are rare with subsequent infusions. No significant increase in
infusion-related reactions is seen in patients treated with
rituximab plus chemotherapy. In the phase II trial of rituximab
plus CHOP vs CHOP alone, grade 3 or 4 infusion-related reactions
were seen in 9% of patients in the rituximab plus CHOP arm, but
all were able to complete planned therapy with no further
recurrence of severe infusion-related reactions (Coiffier et al,
2002). Subgroups of patients who may be at higher risk of
rituximab-associated adverse events have been identified. Patients
with high tumour burden are at increased risk of tumour lysis
syndrome. Those with existing or prior pulmonary or cardiac
complications should also be treated with caution and monitored
because of infusion-related reactions.
Single-agent rituximab induces B-cell depletion in the majority
of patients (McLaughlin et al, 1998). Given this B-cell depletion,
monitoring of infections has been undertaken. During treatment in
the McLaughlin trial (single-agent rituximab in relapsed low-grade
and follicular NHL), 50 of 166 patients developed 68 infectious
events (McLaughlin et al, 1998). Of these, six events (only 9%)
were grade 3 and none grade 4. Prolonged B-cell depletion with
maintenance rituximab also does not seem to result in a significant
increase in infections (Ghielmini et al, 2002; Hainsworth, 2003).
Furthermore, combination studies indicate that the addition of
rituximab to chemotherapy does not significantly increase
clinically relevant toxicity. In the phase III study of rituximab
plus CHOP vs CHOP (Coiffier et al, 2002), the incidence of grade 3
or 4 adverse events was very similar in both arms.
Data on the development of human anti-mouse (HAMA) or
human anti-chimeric antibody (HACA) are available (Rituximab
Summary of Product Characteristics). Of 67 patients evaluated for
HAMA, no responses were observed; of 356 evaluated for HACA,
1.1% (four patients) were positive. These data indicate that
retreatment or maintenance therapy with rituximab remains
feasible: patients may continue responding to repeated rituximab
exposure without developing immune resistance.
FUTURE DIRECTIONS
Several trials are ongoing or planned in order to better define the
role of rituximab in therapy for indolent (Table 2) and aggressive
NHL (Table 3) and for other B-cell disorders. In the indolent
setting there is a growing focus on first-line evaluation, combina-
tion therapy with either chemotherapy or other biological agents,
and rituximab maintenance therapy. Of note is the EBMT Lym-1
trial assessing rituximab in the peritransplant setting both as an in
vivo purge and as maintenance therapy. A BNLI trial of rituximab
vs watchful waiting in patients with advanced-stage asymptomatic
indolent NHL is planned.
In aggressive NHL, data from two ongoing trials are awaited
with interest to confirm the clinical benefit of adding rituximab to
CHOP (or CHOP-like therapy) for elderly patients (ECOG 4494) or
younger patients (MInt) with untreated DLCL (Table 3). Several
smaller phase II studies are evaluating the efficacy of rituximab in
other B-cell disorders, one of which, central nervous system
lymphomas, presents a particular challenge.
In summary, rituximab has shown efficacy and tolerability as
monotherapy in indolent NHL. The data suggest that patients
treated earlier in the course of their disease may respond better to
therapy and that maintenance therapy may provide additional
benefit. In both indolent and aggressive NHL, the use of rituximab
with chemotherapy may provide an advantage over chemotherapy
alone and this is reflected in the number of current and planned
studies of immunochemotherapy. The survival benefit for
rituximab plus CHOP over CHOP alone demonstrated in the
GELA study is awaiting full confirmation by the MInT and ECOG
trials in elderly and younger patients with untreated DLCL. The
general trend seen in NHL is for improved response rates and
quality of response when rituximab is added to chemotherapy:
whether this will translate into improved survival will be




318 Rituximab induction7interferon in untreated indolent NHL. Patients with partial or
minor response receive further rituximab induction7interferon
ECOG 1496 515 Rituximab maintenance after CVP in untreated indolent lymphoma
EORTC-20981 600 CHOP7rituximab7maintenance treatment in relapsed follicular NHL
EBMT Lym-1 460 Rituximab purging and maintenance therapy with ASCT in relapsed follicular NHL
M39021 322 CVP7rituximab in untreated indolent lymphoma




ECOG 4494 631 CHOP7rituximab7maintenance in older patients with diffuse large cell NHL
MInt 820 CHOP7rituximab in younger untreated patients with DLCL
AMC-010 CHOP7rituximab in untreated HIV-associated NHL
RICOVER 60 880 2 2 factorial design: CHOP 147rituximab and six vs eight cycles of chemotherapy
(eight doses rituximab) in older patients with untreated aggressive NHL
CORAL trial 400 Rituximab+ICE vs rituximab+DHAP in relapsed aggressive NHL followed by HDT/
ASCT. Second randomisation to rituximab maintenance vs observation
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Transplantation studies indicate that rituximab in vivo purging
is active and does not compromise ASCT although the role
of both in vivo purging and post-transplant maintenance remains
to be defined. One characteristic central to the integration of
rituximab in these diverse clinical settings is its ability to achieve
not only clinical but molecular responses–the mechanisms of
action of this monoclonal antibody underpin its potential and
utility in the treatment of CD20-positive disorders. An improved
understanding of these mechanisms and the molecular basis of
NHL will help the full therapeutic potential of this agent to be
realised.
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